683 related articles for article (PubMed ID: 29870916)
1. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
Wang X; Shi Y; Huang D; Guan X
Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
[TBL] [Abstract][Full Text] [Related]
2. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
3. Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.
Chen Z; Wang X; Li X; Zhou Y; Chen K
J Int Med Res; 2021 Feb; 49(2):300060521991019. PubMed ID: 33541181
[TBL] [Abstract][Full Text] [Related]
4. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
5. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
6. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
7. Resurrection of PARP Inhibitors in Breast Cancer.
Lyons TG; Robson ME
J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
[TBL] [Abstract][Full Text] [Related]
8. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
Rodriguez-Freixinos V; Fariñas-Madrid L; Gil-Martin M; Barretina-Ginesta P; Romeo M; Villacampa G; Pardo B; Ahmed H; Recalde S; Piulats JM; Gómez-Plaza MC; Gil-Moreno A; Sala E; Martínez-Román S; Ponce J; Meléndez C; Carballas E; Dienstmann R; Oaknin A
Gynecol Oncol; 2019 Feb; 152(2):270-277. PubMed ID: 30551885
[TBL] [Abstract][Full Text] [Related]
10. Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
Sulai NH; Tan AR
Clin Adv Hematol Oncol; 2018 Jul; 16(7):491-501. PubMed ID: 30067621
[TBL] [Abstract][Full Text] [Related]
11. Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
Foote JR; Secord AA; Liang MI; Ehrisman JA; Cohn DE; Jewell E; Havrilesky LJ
Gynecol Oncol; 2019 Mar; 152(3):445-451. PubMed ID: 30876487
[TBL] [Abstract][Full Text] [Related]
12. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
[TBL] [Abstract][Full Text] [Related]
14. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
15. Triple negative breast cancer: new therapeutic approaches and BRCA status.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
APMIS; 2018 May; 126(5):371-379. PubMed ID: 29696717
[TBL] [Abstract][Full Text] [Related]
16. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
[TBL] [Abstract][Full Text] [Related]
17. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
18. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
Papadimitriou M; Mountzios G; Papadimitriou CA
Cancer Treat Rev; 2018 Jun; 67():34-44. PubMed ID: 29753961
[TBL] [Abstract][Full Text] [Related]
19. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.
Geenen JJJ; Linn SC; Beijnen JH; Schellens JHM
Clin Pharmacokinet; 2018 Apr; 57(4):427-437. PubMed ID: 29063517
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
Zhu X; Chen L; Huang B; Li X; Yang L; Hu X; Jiang Y; Shao Z; Wang Z
J Exp Clin Cancer Res; 2021 Apr; 40(1):122. PubMed ID: 33832512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]